229 related articles for article (PubMed ID: 37120775)
1. Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.
Zheng Y; Shen G; Zhang C; Huo X; Xin Y; Fang Q; Guan Y; Zhao F; Ren D; Liu Z; Wang M; Zhao J
Clin Exp Med; 2023 Nov; 23(7):3205-3216. PubMed ID: 37120775
[TBL] [Abstract][Full Text] [Related]
2. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
[TBL] [Abstract][Full Text] [Related]
3. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
Breast Cancer Res; 2024 Apr; 26(1):69. PubMed ID: 38650031
[TBL] [Abstract][Full Text] [Related]
4. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
7. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
[TBL] [Abstract][Full Text] [Related]
8. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M
Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Saura C; Modi S; Krop I; Park YH; Kim SB; Tamura K; Iwata H; Tsurutani J; Sohn J; Mathias E; Liu Y; Cathcart J; Singh J; Yamashita T
Ann Oncol; 2024 Mar; 35(3):302-307. PubMed ID: 38092229
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials.
Ma R; Shi Y; Yan R; Yin S; Bu H; Huang J
Crit Rev Oncol Hematol; 2024 Apr; 196():104305. PubMed ID: 38442809
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Hurvitz SA; Hegg R; Chung WP; Im SA; Jacot W; Ganju V; Chiu JWY; Xu B; Hamilton E; Madhusudan S; Iwata H; Altintas S; Henning JW; Curigliano G; Perez-Garcia JM; Kim SB; Petry V; Huang CS; Li W; Frenel JS; Antolin S; Yeo W; Bianchini G; Loi S; Tsurutani J; Egorov A; Liu Y; Cathcart J; Ashfaque S; Cortés J
Lancet; 2023 Jan; 401(10371):105-117. PubMed ID: 36495879
[TBL] [Abstract][Full Text] [Related]
14. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L;
Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
[TBL] [Abstract][Full Text] [Related]
16. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
[TBL] [Abstract][Full Text] [Related]
17. Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.
Xie XF; Zhang QY; Huang JY; Chen LP; Lan XF; Bai X; Song L; Xiong SL; Guo SJ; Du CW
Breast Cancer Res Treat; 2023 Jan; 197(1):93-101. PubMed ID: 36309908
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
[TBL] [Abstract][Full Text] [Related]
19. Neratinib: an option for HER2-positive metastatic breast cancer.
O'Shaughnessy JA; O'Regan R; Isaacs C
Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]